MarketWatch's Catey Hill and Quentin Fottrell examine some the drastic steps couples have taken to wipe out over six figures worth of debt.

What does it take to succeed financially? MarketWatch's Jonathan Clements and Bankrate.com's Greg McBride join Catey Hill and Quentin Fottrell to break down the most important financial decisions you'll make in a lifetime.

Bankrate.com's Mark Hamrick and Unity Marketing's Pam Danziger join Catey Hill and Quentin Fottrell to explain why while the rich are getting richer, they're not spending as much as you may think.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Bankrate.com's Mark Hamrick and Unity Marketing's Pam Danziger join Catey Hill and Quentin Fottrell to explain why while the rich are getting richer, they're not spending as much as you may think.

eHarmony's new CEO Grant Langston and dating industry analyst Mark Brooks join Catey Hill and Quentin Fottrell to talk the time and money spent in the unique space of online dating, the science behind it, and why eHarmony will never be Tinder.

Learn more about your ad choices. Visit megaphone.fm/adchoices

eHarmony's new CEO Grant Langston and dating industry analyst Mark Brooks join Catey Hill and Quentin Fottrell to talk the time and money spent in the unique space of online dating, the science behind it, and why eHarmony will never be Tinder.

Only 21% of Americans think they'll ever be free from debt. Should you dig your self out of it before diving into marriage? MarketWatch's Jillian Berman joins Catey Hill and Quentin Fottrell to discuss.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Only 21% of Americans think they'll ever be free from debt. Should you dig your self out of it before diving into marriage? MarketWatch's Jillian Berman joins Catey Hill and Quentin Fottrell to discuss.

MarketWatch's Emma Court and Harvard Medical School's Aaron S. Kesselheim join Catey Hill and Quentin Fottrell to talk about how certain drugs, known as biosimilars, can basically replicate existing treatments and save the U.S. health care system $250 billion over the next 10 years.

Learn more about your ad choices. Visit megaphone.fm/adchoices

MarketWatch's Emma Court and Harvard Medical School's Aaron S. Kesselheim join Catey Hill and Quentin Fottrell to talk about how certain drugs, known as biosimilars, can basically replicate existing treatments and save the U.S. health care system $250 billion over the next 10 years.